{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:48:40Z","timestamp":1790110120653,"version":"4.0.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.mayocp.2013.11.002","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T08:15:58Z","timestamp":1391156158000},"page":"225-240","source":"Crossref","is-referenced-by-count":371,"title":["Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies"],"prefix":"10.1016","volume":"89","author":[{"given":"Dean M.","family":"Wingerchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.mayocp.2013.11.002_bib1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7359","key":"10.1016\/j.mayocp.2013.11.002_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"Sawcer","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrneurol.2010.1","article-title":"Environmental factors and their timing in adult-onset multiple sclerosis","volume":"6","author":"Handel","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib5","first-page":"233","article-title":"Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study","volume":"30","author":"Wu","year":"2007","journal-title":"J\u00a0Health Hum Serv Adm"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.002_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1474-4422(10)70135-6","article-title":"Emerging effects of comorbidities on multiple sclerosis","volume":"9","author":"Marrie","year":"2010","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib7","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/1352458511417835","article-title":"Multiple sclerosis and depression","volume":"17","author":"Feinstein","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.mayocp.2013.11.002_bib8","unstructured":"Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global economic impact of multiple sclerosis. 2010. Multiple Sclerosis International Federation website. http:\/\/www.msif.org\/includes\/documents\/cm_docs\/2011\/g\/global_economic_impact_of_ms.pdf?f=1. Accessed August 29,\u00a02013."},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib9","first-page":"639","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature","volume":"16","author":"Adelman","year":"2013","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.mayocp.2013.11.002_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1474-4422(08)70191-1","article-title":"Grey matter pathology in multiple sclerosis","volume":"7","author":"Geurts","year":"2008","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.mayocp.2013.11.002_bib12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol"},{"issue":"9648","key":"10.1016\/j.mayocp.2013.11.002_bib14","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib15","first-page":"455","article-title":"Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines","volume":"27","author":"Simon","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.002_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller","year":"2007","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib20","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.mayocp.2013.11.002_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.20197","article-title":"Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"issue":"8, Suppl 4","key":"10.1016\/j.mayocp.2013.11.002_bib25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.58.8_suppl_4.S3","article-title":"Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis","volume":"58","author":"Dhib-Jalbut","year":"2002","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.mayocp.2013.11.002_bib26","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"issue":"9585","key":"10.1016\/j.mayocp.2013.11.002_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"issue":"9700","key":"10.1016\/j.mayocp.2013.11.002_bib29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"9139","key":"10.1016\/j.mayocp.2013.11.002_bib32","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study","volume":"53","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.002_bib35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"issue":"9139","key":"10.1016\/j.mayocp.2013.11.002_bib36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.002_bib37","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/01.WNL.0000145561.08973.4F","article-title":"Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials","volume":"63","author":"Kappos","year":"2004","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.002_bib38","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib39","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results","volume":"56","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","article-title":"Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis","volume":"9","author":"Polman","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/1352458511426738","article-title":"Persistency of neutralizing antibodies depends on titer and interferon-beta preparation","volume":"18","author":"Hegen","year":"2012","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14737175.6.3.333","article-title":"Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management","volume":"6","author":"Wingerchuk","year":"2006","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib43","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1352458511433302","article-title":"Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence","volume":"18","author":"Giovannoni","year":"2012","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.002_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"issue":"Meeting Abstracts 1","key":"10.1016\/j.mayocp.2013.11.002_bib45","first-page":"S31.006","article-title":"Clinical efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis: data from the Pivotal Phase 3 ADVANCE Study","volume":"80","author":"Calabresi","year":"2013","journal-title":"Neurology"},{"issue":"9350","key":"10.1016\/j.mayocp.2013.11.002_bib46","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.mayocp.2013.11.002_bib47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","article-title":"Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"issue":"25","key":"10.1016\/j.mayocp.2013.11.002_bib48","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib49","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib50","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4 Multiple Sclerosis","key":"10.1016\/j.mayocp.2013.11.002_bib51","first-page":"968","article-title":"Present and emerging therapies for multiple sclerosis","volume":"19","author":"Freedman","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.11.002_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"issue":"20","key":"10.1016\/j.mayocp.2013.11.002_bib55","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.11.002_bib56","series-title":"Global natalizumab (TYSABRI) safety update","year":"2013"},{"issue":"10","key":"10.1016\/j.mayocp.2013.11.002_bib57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.002_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"issue":"23","key":"10.1016\/j.mayocp.2013.11.002_bib60","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2013.11.002_bib61","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib63","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.mayocp.2013.11.002_bib64","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.mayocp.2013.11.002_bib65","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1212\/WNL.0b013e318275979d","article-title":"Lethal multiple sclerosis relapse after natalizumab withdrawal","volume":"79","author":"Rigau","year":"2012","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.mayocp.2013.11.002_bib66","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting?","volume":"68","author":"West","year":"2010","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib69","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"issue":"Meeting Abstracts 1","key":"10.1016\/j.mayocp.2013.11.002_bib70","first-page":"S41.002","article-title":"ENIGM: a French observational study about switching from natalizumab to fingolimod in multiple sclerosis","volume":"80","author":"Cohen","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.002_bib71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-1331.2012.03794.x","article-title":"Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab","volume":"20","author":"Rossi","year":"2013","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib73","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib74","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann Neurol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2013.11.002_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia","volume":"256","author":"Noda","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"issue":"19","key":"10.1016\/j.mayocp.2013.11.002_bib76","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3182735d00","article-title":"Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod","volume":"79","author":"Ratchford","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.mayocp.2013.11.002_bib77","series-title":"Gilenya [package insert]","year":"2012"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema: incidence, detection, and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.mayocp.2013.11.002_bib79","unstructured":"FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). Food and Drug Adminstration website. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm366529.htm. Accessed September 6,\u00a02013."},{"issue":"1","key":"10.1016\/j.mayocp.2013.11.002_bib80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","article-title":"Immune mechanisms of new therapeutic strategies in MS: teriflunomide","volume":"142","author":"Claussen","year":"2012","journal-title":"Clin Immunol"},{"issue":"14","key":"10.1016\/j.mayocp.2013.11.002_bib81","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Meeting Abstracts 1","key":"10.1016\/j.mayocp.2013.11.002_bib82","first-page":"S01.004","article-title":"Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second, pivotal, phase 3 placebo-controlled study","volume":"80","author":"Miller","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/CPJ.0b013e318296f299","article-title":"Teriflunomide","volume":"3","author":"Oh","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.mayocp.2013.11.002_bib84","series-title":"Aubagio [package insert]","year":"2013"},{"key":"10.1016\/j.mayocp.2013.11.002_bib85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","article-title":"Benefit-risk assessment of leflunomide: an appraisl of leflunomide in rheumatoid arthritis 10 years after licensing","volume":"32","author":"Alcorn","year":"2009","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.002_bib86","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/17425255.2013.800483","article-title":"Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis","volume":"9","author":"Wiese","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Pt 3","key":"10.1016\/j.mayocp.2013.11.002_bib87","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.mayocp.2013.11.002_bib88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1742-2094-9-163","article-title":"Effects of dimethyl fumarate on neuroprotection and immunomodulation","volume":"9","author":"Albrecht","year":"2012","journal-title":"J\u00a0Neuroinflammation"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib89","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMe1209169","article-title":"The \u201cpoison chair\u201d treatment for multiple sclerosis","volume":"367","author":"Ropper","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib90","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib91","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.11.002_bib92","series-title":"Tecfidera [package insert]","year":"2013"},{"issue":"17","key":"10.1016\/j.mayocp.2013.11.002_bib93","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","article-title":"PML in a patient treated with fumaric acid","volume":"368","author":"Ermis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2013.11.002_bib94","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2013.11.002_bib95","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","article-title":"Manufacturer's response to case reports of PML","volume":"368","author":"Sweetser","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9856","key":"10.1016\/j.mayocp.2013.11.002_bib96","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.mayocp.2013.11.002_bib97","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.002_bib98","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib99","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.mayocp.2013.11.002_bib100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1468-1331.2011.03507.x","article-title":"A\u00a0single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis","volume":"19","author":"Fox","year":"2012","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib101","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib102","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"issue":"9805","key":"10.1016\/j.mayocp.2013.11.002_bib103","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib104","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1212\/WNL.54.9.1726","article-title":"Linomide in relapsing and secondary progressive MS, Part I: trial design and clinical results","volume":"54","author":"Noseworthy","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mayocp.2013.11.002_bib105","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2013.11.002_bib106","first-page":"S507","article-title":"A\u00a0placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis","volume":"17","author":"Vollmer","year":"2011","journal-title":"MSJ"},{"issue":"23","key":"10.1016\/j.mayocp.2013.11.002_bib107","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.002_bib108","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/01.wnl.0000267662.41734.1f","article-title":"Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results","volume":"69","author":"Rose","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib109","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1177\/1352458511414755","article-title":"Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis","volume":"17","author":"Sheridan","year":"2011","journal-title":"Mult Scler"},{"issue":"9884","key":"10.1016\/j.mayocp.2013.11.002_bib111","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.mayocp.2013.11.002_bib112","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib113","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2012.7625","article-title":"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis","volume":"308","author":"Shirani","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000189271","article-title":"Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients","volume":"61","author":"Portaccio","year":"2009","journal-title":"Eur Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/1352458510379245","article-title":"A\u00a0method for evaluating treatment switching criteria in multiple sclerosis","volume":"16","author":"Healy","year":"2010","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.mayocp.2013.11.002_bib116","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneurol.2013.146","article-title":"Defining and scoring response to IFN-beta in multiple sclerosis","volume":"9","author":"Sormani","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1016\/j.mayocp.2013.11.002_bib117","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","article-title":"MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials","volume":"12","author":"Sormani","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/jnnp-2011-301178","article-title":"Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis","volume":"83","author":"Goodin","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib119","first-page":"405","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.002_bib120","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40263-013-0065-y","article-title":"Induction therapy for patients with multiple sclerosis: why? when? how?","volume":"27","author":"Edan","year":"2013","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.mayocp.2013.11.002_bib121","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0022-510X(09)70012-7","article-title":"Concepts of induction and escalation therapy in multiple sclerosis","volume":"277","author":"Rieckmann","year":"2009","journal-title":"J\u00a0Neurol Sci"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib122","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2010.229724","article-title":"French\u2013Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial","volume":"82","author":"Edan","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib123","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1352458507085759","article-title":"Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis","volume":"14","author":"Vollmer","year":"2008","journal-title":"Mult Scler"},{"issue":"20","key":"10.1016\/j.mayocp.2013.11.002_bib124","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2013.11.002_bib126","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"Randomized study combining interferon and glatiramer acetate in multiple sclerosis","volume":"73","author":"Lublin","year":"2013","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.mayocp.2013.11.002_bib127","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000319698.40024.1c","article-title":"Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis","volume":"71","author":"Birnbaum","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mayocp.2013.11.002_bib128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon \u03b2-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2013.11.002_bib129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrneurol.2011.164","article-title":"Multiple sclerosis: combination therapy in MS\u2014still a valid strategy","volume":"7","author":"Kieseier","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"Pt 12","key":"10.1016\/j.mayocp.2013.11.002_bib130","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A\u00a0type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.mayocp.2013.11.002_bib131","doi-asserted-by":"crossref","first-page":"e19262","DOI":"10.1371\/journal.pone.0019262","article-title":"Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis","volume":"6","author":"Rudick","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.mayocp.2013.11.002_bib132","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T\u00a0helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.mayocp.2013.11.002_bib133","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1212\/WNL.0b013e318259e123","article-title":"Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS","volume":"79","author":"Bushnell","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.mayocp.2013.11.002_bib134","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1741-7015-10-116","article-title":"Personalized medicine in multiple sclerosis: hope or reality?","volume":"10","author":"Derfuss","year":"2012","journal-title":"BMC Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613009865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619613009865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T21:20:54Z","timestamp":1538860854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619613009865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0025619613009865"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2013.11.002","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}